Jack Donlon, Pooja Kumari, Sajoy P Varghese, Michael Bai, Ori David Florentin, Emma D Frost, John Banks, Niyathi Vadlapatla, Olivia Kam, Mujeeb U Shad, Shafiqur Rahman, Osama A Abulseoud, Trevor W Stone, Maju Mathew Koola
The detrimental physical, mental, and socioeconomic effects of substance use disorders (SUDs) have been apparent to the medical community for decades. However, it has become increasingly urgent in recent years to develop novel pharmacotherapies to treat SUDs. Currently, practitioners typically rely on monotherapy. Monotherapy has been shown to be superior to no treatment at all for most substance classes. However, many randomized controlled trials (RCTs) have revealed that monotherapy leads to poorer outcomes when compared with combination treatment in all specialties of medicine...
December 20, 2023: Journal of Dual Diagnosis